eligibility_summary
Adults 18–75 with relapsed/refractory CD70+ T‑cell lymphoma (ALCL must be BV‑exposed/resistant) or AML, ECOG 0–2, survival ≥12 wks, adequate organ, O2 and cardiac function, prior auto‑HSCT (once) or failed/relapsed CAR‑T allowed, washout complete, negative pregnancy and contraception, two negative COVID/Flu A. Exclude: active infections, HBV/HCV (except low‑DNA HBV), HIV, significant GvHD post‑allo‑HSCT, NYHA III/IV, unresolved ≥G2 AEs, CNS disease, recent gene therapy, positive COVID/Flu A.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: CD70 CAR-NK (biological, genetically engineered allogeneic cell therapy from cord blood). Mechanism: Natural killer cells are modified with a chimeric antigen receptor that binds CD70 on tumor cells, triggering NK-mediated cytotoxicity (perforin/granzyme) while retaining innate NK tumor-killing capacity. Target engagement may also disrupt the CD70/CD27 signaling axis implicated in tumor growth. Rationale: CD70 is overexpressed on T-cell lymphoma (TCL) and acute myeloid leukemia (AML) cells but minimal on normal tissues and hematopoietic stem cells, reducing on-target/off-tumor risk and avoiding T-cell fratricide seen with CAR-T in TCL. Targets: CD70-positive TCL cells and AML blasts, CD70/CD27 pathway. Design: Phase 1, single-arm dose escalation (3 levels) followed by expansion to assess safety, pharmacokinetics, and preliminary efficacy in relapsed/refractory, CD70-positive TCL and AML.